A Rybelsus coupon still exists in the US, but it is ending: Novo Nordisk's Rybelsus savings card (pay as little as $25, savings capped at $100 a month, commercial insurance only) states that it expires December 31, 2026, and Rybelsus itself is being discontinued and replaced by Ozempic tablets. As of November 4, 2026, the Ozempic tablets savings offer lets commercially insured patients with coverage for the 1.5, 4 or 9 mg pill pay as little as $25, with maximum savings of $100, $200 or $300 per 1-, 2- or 3-month fill. Medicare, Medicaid, VA, DOD and TRICARE enrollees are excluded. Without coverage, Novo's self-pay price for Ozempic tablets is $149, $199 or $299 a month by dose.
Rybelsus (oral semaglutide) carried a last published list price of $997.58 per package for the 7 mg and 14 mg strengths, and real-world pharmacy cash prices ran higher still. Novo Nordisk's official coupon, the Rybelsus Savings Offer, cuts that to almost nothing, but the fine print excludes the people who need help most: anyone paying cash or on a government plan.
Direct answer: With the official Rybelsus savings card, eligible commercially insured patients pay as little as $25 per fill, subject to a maximum savings of $100 per 1-month prescription, $200 per 2-month prescription, or $300 per 3-month prescription (7 mg and 14 mg; the 3 mg starter dose is limited to 1-month fills with a $100 cap). Activations are described as valid for up to 48 months from enrollment, but the Rybelsus offer itself states it expires December 31, 2026, and the old Rybelsus savings page on NovoCare now redirects to the Ozempic savings offer. The replacement Ozempic tablets card has the same $25 / $100-per-month structure. If you pay cash, neither card applies: remaining Rybelsus stock runs about $974.77 with a GoodRx coupon (June 2026), while Ozempic tablets have a manufacturer self-pay price of $149-$299/month. There is no Rybelsus generic, and none is expected before the early 2030s.
Heads up (updated November 2026): Rybelsus is being discontinued in the US and replaced by Ozempic tablets (oral semaglutide 1.5/4/9 mg, $149/$199/$299 self-pay). Wholesaler shipments stopped in May 2026 and pharmacy stock has been limited since about July. The doses are not interchangeable mg-for-mg: Rybelsus 7 mg corresponds to Ozempic tablets 4 mg, and Rybelsus 14 mg to Ozempic tablets 9 mg. If you're starting fresh rather than refilling, use the Ozempic tablets offer, not the Rybelsus card.
Rybelsus is FDA approved for type 2 diabetes, so the savings card rides on a T2D prescription that your commercial plan covers. Ozempic tablets share the same FDA label and indications. For what the drug does and who it suits, see our Rybelsus guide.
Rybelsus Savings Card: Official 2026 Terms
Novo Nordisk updated the offer terms effective January 2, 2026. The current structure, from the NovoCare savings card program page:
| Dose | You pay | Maximum savings | Fill length allowed |
|---|---|---|---|
| Rybelsus 3 mg | As little as $25 | $100 per 1-month fill | 1-month fills only |
| Rybelsus 7 mg | As little as $25 | $100 / $200 / $300 | 1-, 2-, or 3-month |
| Rybelsus 14 mg | As little as $25 | $100 / $200 / $300 | 1-, 2-, or 3-month |
Two things to notice. First, the $100-per-month savings cap means the card only gets you to $25 if your insurance already covers Rybelsus and your copay is $125 or less. If your plan covers the drug but sticks you with a $250 copay, the card knocks off $100 and you pay $150. Second, while card activations are described as valid for up to 48 months, the same NovoCare terms say the Rybelsus offer expires December 31, 2026. Plan to move to the Ozempic tablets card before then.
Rybelsus Is Being Replaced by Ozempic Tablets: What It Means for Price
The Rybelsus card is on its way out, but the replacement offer is at least as good: Ozempic tablets come with the same "as little as $25" commercial savings card and, unlike Rybelsus, a manufacturer self-pay price of $149 to $299 a month for people without coverage.
The FDA approved Ozempic tablets on February 4, 2026, for adults with type 2 diabetes, and Novo launched them nationwide on May 4, 2026 (Novo Nordisk Form 6-K, Q1 2026). FDA's drug shortage database lists Rybelsus 3 mg, 7 mg and 14 mg as "To Be Discontinued," noting they "will be replaced by Ozempic (semaglutide) tablets." Both products share one FDA label with the same indications and administration.
| Rybelsus savings card | Ozempic tablets savings card | |
|---|---|---|
| Doses covered | 3 mg (1-month fills only), 7 mg, 14 mg | 1.5 mg, 4 mg, 9 mg |
| You pay (commercial coverage) | As little as $25 | As little as $25 |
| Maximum savings | $100 / $200 / $300 per 1- / 2- / 3-month fill | $100 / $200 / $300 per 1- / 2- / 3-month fill |
| Offer end date | December 31, 2026 | None stated in the terms; Novo can change or end it at any time |
| Government plans (Medicare, Medicaid, VA, DOD, TRICARE) | Excluded | Excluded |
| Self-pay price without insurance | None offered | $149 (1.5 mg), $199 (4 mg), $299 (9 mg) a month |
| List price, 30 tablets | $997.58 (last published) | $1,027.51 |
Source: NovoCare Diabetes Savings Offer terms, checked November 4, 2026. A "month" is one 30-tablet bottle; the 3-month fill requires a 3-month prescription and a plan that covers 3-month fills.
What this means for your coupon:
- Switching needs a new prescription. Per the label, Rybelsus 7 mg = Ozempic tablets 4 mg and Rybelsus 14 mg = Ozempic tablets 9 mg, and "RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis."
- Re-check coverage first. Some payers automatically transferred Rybelsus prior authorizations to Ozempic tablets; others did not. The $25 price only applies if your plan covers the pill.
- The Ozempic tablets card has one extra trap worth knowing: it can't be used if your insurer runs an accumulator or copay-maximizer program, and Novo can cut or end savings if it detects one.
- Medicare: neither card works with Medicare. Novo's self-pay terms let Medicare enrollees buy Ozempic tablets at the self-pay price outside their plan, but that spending can't be counted toward Part D deductibles or out-of-pocket limits.
- 2027 list price: Novo announced on February 24, 2026 that the list price of its semaglutide medicines, naming "Rybelsus® (semaglutide) tablets 7 mg or 14 mg," falls to $675 a month on January 1, 2027. Self-pay prices aren't affected. The cut matters most if you're on a high-deductible plan or coinsurance; with a fixed copay and the $25 card, your cost likely won't change.
Who Qualifies for the Rybelsus Manufacturer Coupon
The eligibility rules, straight from NovoCare (the Ozempic tablets card uses the same commercial-insurance rules):
- Commercial or private insurance required. The offer "excludes full cash-paying patients" — no insurance, no card.
- Government insurance disqualifies you: Medicaid, Medicare, VA, DOD, and TRICARE enrollees cannot use it.
- Exceptions that count as commercial: FEHB plans, Affordable Care Act marketplace plans, and state employee plans are not treated as government programs for this offer.
- Enrollment: sign up at NovoCare online or text READY to 21848 (LISTO for Spanish), verify eligibility, confirm treatment details, and download the card or receive it by text.
Rybelsus Cost Without Insurance
If the manufacturer coupon is closed to you, here is the retail landscape for remaining Rybelsus stock. Rybelsus's last published list price was $997.58 per package, and pharmacy cash prices typically landed between $950 and $1,100 per month (June 2026):
| Pharmacy | Cash price (30-day supply) |
|---|---|
| Rite Aid | $996.60 |
| Target / CVS | $1,007 |
| Walgreens | $1,028 |
| Walmart | $1,043 |
| Costco | $1,105 |
Rybelsus is also not included in Novo Nordisk's 2026 Patient Assistance Program, and unlike the Ozempic pen, which has a $349-$499/month self-pay price, Novo never offered a manufacturer cash-pay program for Rybelsus. Its replacement changes that: Ozempic tablets self-pay at $149 (1.5 mg), $199 (4 mg) or $299 (9 mg) a month, a fraction of cash-pay Rybelsus. Our GLP-1 cost breakdown covers the full pricing picture across the class.
No insurance, or your plan won't cover Rybelsus? SkinnyRx — an online intake reviewed by a licensed provider, who decides whether prescription treatment is appropriate. Compounded semaglutide and tirzepatide as weekly injections or daily tablets, plus FDA-approved options through the SkinnyRx Membership. (Partner link: we may earn a commission. Compounded drugs are not FDA-approved or evaluated for safety, effectiveness or quality by the FDA.)
Rybelsus Price With a GoodRx Coupon
GoodRx coupons work for anyone (no insurance required) and shaved roughly $130-$275 off retail in June 2026, where a pharmacy still has Rybelsus in stock:
| Dose (30 tablets) | Average retail | GoodRx price |
|---|---|---|
| 3 mg | $1,248.69 | $974.77 |
| 7 mg | $1,245.32 | $1,014.72 |
| 14 mg | $1,146.53 | $1,013.86 |
That is real money, but it still leaves you around $1,000/month. GoodRx is a fallback, not a solution, for a drug at this price point, and Novo's self-pay price for Ozempic tablets is far lower. Note you cannot stack GoodRx with insurance or with the manufacturer card on the same fill.
Is There a Rybelsus Generic?
No. There is currently no generic Rybelsus, and the timeline is long: semaglutide's primary US compound patent runs to December 2031, patent-litigation settlements point to generic injectable semaglutide entering around 2032, and Rybelsus's oral-formulation patent extends to 2039. Generic semaglutide may arrive earlier outside the US (Canada's primary patent expires in 2026), but importing it is not a legal pathway for US patients. Anyone selling "generic Rybelsus" in the US today is selling something else.
Cheaper Oral Semaglutide Alternatives
The Rybelsus coupon math only matters if Rybelsus is still the product you're getting. Several oral options now undercut it badly on cash price:
- Ozempic tablets (oral semaglutide): Rybelsus's US replacement, with the same type 2 diabetes label. $149 / $199 / $299 a month self-pay at 1.5 / 4 / 9 mg, or as little as $25 with commercial coverage and the savings card.
- Wegovy pill (oral semaglutide): approved for weight management, $149/month self-pay at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg through NovoCare (as of November 4, 2026). If your real goal is weight loss rather than A1C control, this is dramatically cheaper than cash-pay Rybelsus.
- Foundayo (orforglipron): Lilly's oral GLP-1, self-pay from $149-$299/month by dose. Also a weight-management drug, not a T2D substitute.
- Compounded semaglutide: oral or injectable, typically $146-$300/month through licensed US pharmacies via telehealth.
For type 2 diabetes specifically, Ozempic tablets (or Rybelsus while stock lasts) with the savings card ($25-$150/month effective) is hard to beat if you have commercial coverage. Without it, compare every option in our cheapest GLP-1 ranking and our master list of GLP-1 drug coupons and savings programs.
Frequently Asked Questions
How much is Rybelsus with the savings card? As little as $25 per month, but only if you have commercial insurance that covers Rybelsus and your copay is within $125. The card's savings are capped at $100 per 1-month fill ($300 per 3-month fill on 7 mg and 14 mg), and the Rybelsus offer expires December 31, 2026.
Can I use the Rybelsus coupon without insurance? No. Novo Nordisk's terms explicitly exclude full cash-paying patients and anyone on Medicare, Medicaid, VA, DOD, or TRICARE. Cash payers can use GoodRx on remaining Rybelsus stock (~$975-$1,015) or, more cheaply, Novo's self-pay price for Ozempic tablets: $149 / $199 / $299 a month at 1.5 / 4 / 9 mg.
Does the Rybelsus savings card expire? Yes. NovoCare's terms state the Rybelsus offer expires December 31, 2026; current pricing terms took effect January 2, 2026. Activations are described as valid for up to 48 months, but that doesn't extend the offer past its end date. The Ozempic tablets card is the replacement.
Is there a generic for Rybelsus? No. Key semaglutide patents run to December 2031 with the oral-formulation patent out to 2039; realistic US generic entry for any semaglutide is around 2032, and later for the oral form.
Why is Rybelsus so expensive without insurance? It is a patented, brand-only drug with no manufacturer cash program, unlike the Ozempic pen, which Novo sells direct for $349-$499/month, and Ozempic tablets, which self-pay at $149-$299/month. Retail cash prices for Rybelsus ran $950-$1,105 depending on pharmacy.
Is there an Ozempic tablets coupon? Yes. As of November 4, 2026, the NovoCare savings offer lets commercially insured patients with coverage for Ozempic tablets 1.5 mg, 4 mg or 9 mg pay as little as $25, with maximum savings of $100 per 1-month, $200 per 2-month, or $300 per 3-month fill. Government-plan enrollees are excluded. Without coverage, the self-pay price is $149, $199 or $299 a month by dose.
Is Rybelsus being discontinued in the US? Yes. Novo Nordisk is replacing Rybelsus with Ozempic tablets, launched May 4, 2026. FDA's drug shortage database lists Rybelsus 3 mg, 7 mg and 14 mg as "To Be Discontinued." Pharmacies may still dispense remaining stock, which has been limited since about July 2026. Outside the US, Rybelsus is still sold under that name.
Can I switch my Rybelsus prescription to Ozempic tablets and keep the $25 price? Usually, if your plan covers Ozempic tablets. You need a new prescription (Rybelsus 7 mg = Ozempic tablets 4 mg; 14 mg = 9 mg), then enroll in the Ozempic tablets savings offer. Some payers automatically moved Rybelsus prior authorizations to Ozempic tablets, but not all, so confirm with your plan.
Will Rybelsus get cheaper in 2027? The list price will. Novo announced that the list price of its semaglutide medicines, including Rybelsus 7 mg and 14 mg tablets, drops to $675 a month from January 1, 2027. Self-pay prices aren't affected, and with a fixed copay plus the $25 card your cost likely stays the same.
Last reviewed: November 4, 2026
Sources
- Diabetes Savings Card Program — NovoCare
- Rybelsus Savings Offer — NovoCare
- Explaining the List Price of Rybelsus — NovoCare
- Rybelsus Prices, Coupons & Savings Tips — GoodRx
- Rybelsus Cost Without Insurance: 2026 Prices — Noom
- Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic — PR Newswire
- The patent landscape for Novo Nordisk's semaglutide products — Markman Advisors
- Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk — BioPharma Dive
- Explaining the List Price of Ozempic (pen and pill) — NovoCare
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus — Novo Nordisk, February 24, 2026
- FDA Drug Shortages database (Rybelsus "To Be Discontinued") — FDA
References
- Semaglutide — StatPearls (NCBI Bookshelf): FDA-approved indications and mechanism, including oral semaglutide (Rybelsus) for type 2 diabetes
- PIONEER 1: randomized clinical trial of oral semaglutide monotherapy in type 2 diabetes (Diabetes Care; PubMed, PMID 31186300)
- OZEMPIC tablets and RYBELSUS (oral semaglutide) label, revised 1/2026 — DailyMed
- Novo Nordisk Form 6-K, Q1 2026 (Ozempic tablets approval and US launch) — SEC









